Immune therapy for pharmacoresistant epilepsy: ready to go?

Despite the introduction of almost 20 new antiseizure drugs in the last several decades, approximately 30% of patients with epilepsy have pharmacoresistant seizures. Although many genetic disorders and cerebral structural lesions are known causes of difficult-to-treat epilepsy, some refractory patients do not fall into these categories. In the search for other etiologic factors, the multiple and close interactions between the immune system and epilepsy have gained substantial interest.(1.)